Freedom of Information request on disclosure of full responses to the MHRA public consultation on the proposal to make Dovonex Psoriasis 50mcg/g ointment (PL 00043/0219) available through Pharmacies (FOI 21/1188)
Published 26 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-8-november-2021/freedom-of-information-request-on-disclosure-of-full-responses-to-the-mhra-public-consultation-on-the-proposal-to-make-dovonex-psoriasis-50mcgg-ointm
FOI 21/1188
12th November 2021
Dear,
Thank you for your information request, dated 2nd November 2021, where you asked for the disclosure of full responses to the MHRA public consultation on the proposal to make Dovonex Psoriasis 50mcg/g ointment (PL 00043/0219) available through Pharmacies as made by the Chief Executive of the Dispensing Doctor’s Association.
The redacted document which you have attached to your email is the full response provided from the Chief Executive of the Dispensing Doctor’s Association in relation to the public consultation for Dovonex Psoriasis 50mcg/g ointment. The information which is redacted cannot be disclosed and is exempt from release under Section 40 of the FOI Act:
Section 40 (Personal information): Section 40 protects personal data, the disclosure of which would breach one or more of the data protection principles. The Agency is satisfied that disclosure here would breach the first data protection principle, in particular the requirement of fairness on the basis that disclosure would not be reasonably expected by the people mentioned in the information.
If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review will be carried out by a senior member of the Agency who was not involved with the original decision.
If you have a query about the information provided, please reply to this email.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division